Compare Bristol-Myers Squibb Co (BMY) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Weibo Corp — how do they compare? Bristol-Myers Squibb Co trades at $58.7 (market cap $116.30B), while Weibo Corp trades at $7.72 (market cap $1.88B). The key difference: Bristol-Myers Squibb Co is far larger — about 61.9× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.96%). Which is the better fit depends on your goals.
| BMY | WB | |
|---|---|---|
Market Cap | $116.30B | $1.88B |
Sector | Health | Media |
52-Week High | $62.37 | $12.83 |
52-Week Low | $42.60 | $7.20 |
Enterprise Value | $152.24B | $1.16B |
Dividend Yield | 4.42% | 7.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Weibo (WB) trades at $7.67, down 0.65% on the day, with a bullish technical signal from moving averages and strong valuation metrics including a P/E of 5.37 and P/B of 0.49. The company reported $449.02M net income for 2025 with a 25.55% margin, though recent quarters saw EPS misses. A $0.61 dividend for H1-26 is scheduled, and cash flow trends show improvement in 2025. Analyst sentiment is mixed with 45% buy ratings.
The outlook balances deep value against competitive pressures. Upside is supported by low multiples and robust cash flow, but risks include user engagement challenges from rivals like Douyin and inconsistent earnings performance. The stock presents a value opportunity with income, yet requires monitoring of competitive and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
